Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Entera Bio Ltd., a foreign private issuer based in Jerusalem, Israel, for the month of August 2018. The filing date is August 9, 2018. The report consists solely of a press release incorporated by reference regarding corporate governance changes.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed in this filing is the appointment of Mr. Gerald Lieberman as Chairman of the Board of Directors. No financial or operational changes were reported in this document.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The content is limited to the announcement of the board appointment.
Key Facts for Investor Verification
- Mr. Gerald Lieberman has been appointed Chairman of the Board of Directors.
- The filing is a Form 6-K submitted on August 9, 2018, incorporating a press release as Exhibit 99.1.
- Dr. Phillip Schwartz, Chief Executive Officer, signed the report on behalf of the registrant.
- No financial data is included in this specific filing; investors should refer to the most recent Form 20-F or quarterly reports for financial status.